158 related articles for article (PubMed ID: 12932672)
1. The combination of yondelis and cisplatin is synergistic against human tumor xenografts.
D'Incalci M; Colombo T; Ubezio P; Nicoletti I; Giavazzi R; Erba E; Ferrarese L; Meco D; Riccardi R; Sessa C; Cavallini E; Jimeno J; Faircloth GT
Eur J Cancer; 2003 Sep; 39(13):1920-6. PubMed ID: 12932672
[TBL] [Abstract][Full Text] [Related]
2. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.
Meco D; Colombo T; Ubezio P; Zucchetti M; Zaffaroni M; Riccardi A; Faircloth G; Jose J; D'Incalci M; Riccardi R
Cancer Chemother Pharmacol; 2003 Aug; 52(2):131-8. PubMed ID: 12783202
[TBL] [Abstract][Full Text] [Related]
3. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.
Hendriks HR; Fiebig HH; Giavazzi R; Langdon SP; Jimeno JM; Faircloth GT
Ann Oncol; 1999 Oct; 10(10):1233-40. PubMed ID: 10586342
[TBL] [Abstract][Full Text] [Related]
4. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.
Riccardi A; Meco D; Ubezio P; Mazzarella G; Marabese M; Faircloth GT; Jimeno J; D'Incalci M; Riccardi R
Anticancer Drugs; 2005 Sep; 16(8):811-5. PubMed ID: 16096428
[TBL] [Abstract][Full Text] [Related]
5. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
6. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts.
Valoti G; Nicoletti MI; Pellegrino A; Jimeno J; Hendriks H; D'Incalci M; Faircloth G; Giavazzi R
Clin Cancer Res; 1998 Aug; 4(8):1977-83. PubMed ID: 9717828
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Twelves C; Hoekman K; Bowman A; Vermorken JB; Anthoney A; Smyth J; van Kesteren C; Beijnen JH; Uiters J; Wanders J; Gomez J; Guzmán C; Jimeno J; Hanauske A
Eur J Cancer; 2003 Sep; 39(13):1842-51. PubMed ID: 12932661
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
Sessa C; De Braud F; Perotti A; Bauer J; Curigliano G; Noberasco C; Zanaboni F; Gianni L; Marsoni S; Jimeno J; D'Incalci M; Dall'ó E; Colombo N
J Clin Oncol; 2005 Mar; 23(9):1867-74. PubMed ID: 15774779
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.
Leporini C; Patanè M; Saullo F; Rende P; Gallelli L; Di Paola ED; Toscano R; Lucia M; Rossi M; De Sarro G; Russo E
BioDrugs; 2014 Dec; 28(6):499-511. PubMed ID: 25209722
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
Sessa C; Cresta S; Noberasco C; Capri G; Gallerani E; De Braud F; Zucchetti M; D'Incalci M; Locatelli A; Marsoni S; Corradino I; Minoia C; Zintl P; Gianni L
Eur J Cancer; 2009 Aug; 45(12):2116-22. PubMed ID: 19419856
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin combined with the new cisplatin-procaine complex DPR: in vitro and in vivo studies.
Viale M; Vannozzi MO; Merlo F; Cafaggi S; Parodi B; Esposito M
Eur J Cancer; 1996 Dec; 32A(13):2327-33. PubMed ID: 9038617
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line.
Formelli F; Cleris L
Eur J Cancer; 2000 Dec; 36(18):2411-9. PubMed ID: 11094318
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice.
Shalinsky DR; Bischoff ED; Gregory ML; Lamph WW; Heyman RA; Hayes JS; Thomazy V; Davies PJ
Clin Cancer Res; 1996 Mar; 2(3):511-20. PubMed ID: 9816198
[TBL] [Abstract][Full Text] [Related]
19. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells.
Levasseur LM; Greco WR; Rustum YM; Slocum HK
Cancer Chemother Pharmacol; 1997; 40(6):495-505. PubMed ID: 9332464
[TBL] [Abstract][Full Text] [Related]
20. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
